Hydroxymethylglutaryl-CoA Reductase Inhibitors

"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.

Descriptor ID	D019161
MeSH Number(s)	D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
Concept/Terms	Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl CoA Reductase Inhibitors Inhibitors, Hydroxymethylglutaryl-CoA Reductase Reductase Inhibitors, Hydroxymethylglutaryl-CoA Inhibitors, HMG-CoA Reductase Inhibitors, HMG CoA Reductase Reductase Inhibitors, HMG-CoA HMG-CoA Reductase Inhibitors HMG CoA Reductase Inhibitors Statins, HMG-CoA HMG-CoA Statins Statins, HMG CoA Inhibitors, Hydroxymethylglutaryl-CoA Hydroxymethylglutaryl-CoA Inhibitors Inhibitors, Hydroxymethylglutaryl CoA Statins Inhibitors, Hydroxymethylglutaryl-Coenzyme A Hydroxymethylglutaryl-Coenzyme A Inhibitors Inhibitors, Hydroxymethylglutaryl Coenzyme A

Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Hypolipidemic Agents [D27.505.519.186.071]
Anticholesteremic Agents [D27.505.519.186.071.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.186.071.202.370]
Enzyme Inhibitors [D27.505.519.389]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.389.370]
Therapeutic Uses [D27.505.954]
Lipid Regulating Agents [D27.505.954.557]
Hypolipidemic Agents [D27.505.954.557.500]
Anticholesteremic Agents [D27.505.954.557.500.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.954.557.500.202.370]

Below are MeSH descriptors whose meaning is related to "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 155 publications over 24 distinct years, with a maximum of 13 publications in 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2002	1	0	1
2003	2	0	2
2004	9	0	9
2005	3	1	4
2006	6	6	12
2007	5	1	6
2008	3	4	7
2009	5	1	6
2010	4	3	7
2011	5	4	9
2012	10	3	13
2013	4	1	5
2014	10	2	12
2015	3	3	6
2016	7	4	11
2017	7	0	7
2018	6	2	8
2019	6	2	8
2020	4	0	4
2021	7	2	9
2022	5	0	5
2023	2	0	2
2024	1	0	1

Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.

Bardoczi JB, Rossen M, Eugster N, Agoritsas T, Gencer B, Rodondi N. [For which patients do the latest lipid lowering treatments reduce cardiovascular events?] Rev Med Suisse. 2024 Mar 06; 20(864):472-479.

View in: PubMed
Titus A, Cheema HA, Shafiee A, Seighali N, Shahid A, Bhanushali KB, Kumar A, Khan SU, Khadke S, Thavendiranathan P, Hundley WG, Scherrer-Crosbie M, Nohria A, Neilan TG, Dani SS, Nasir K, Ganatra S. Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis. Curr Probl Cardiol. 2023 Oct; 48(10):101885.

View in: PubMed
Virani SS, Ramsey DJ, Westerman D, Kuebeler MK, Chen L, Akeroyd JM, Gobbel GT, Ballantyne CM, Petersen LA, Turchin A, Matheny ME. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease. Circulation. 2023 05 02; 147(18):1411-1413.

View in: PubMed
Fabrizio VA, Lindsay CV, Wilcox M, Hong S, Lynn T, Norwitz ER, Yonkers KA, Abrahams VM. The serotonin reuptake inhibitor fluoxetine induces human fetal membrane sterile inflammation through p38 MAPK activation. J Reprod Immunol. 2023 02; 155:103786.

View in: PubMed
Degrush E, Shazeeb MS, Drachman D, Vardar Z, Lindsay C, Gounis MJ, Henninger N. Cumulative effect of simvastatin, L-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer's disease. Alzheimers Res Ther. 2022 09 17; 14(1):134.

View in: PubMed
Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, Coker TR, Davis EM, Donahue KE, Ja?n CR, Kubik M, Li L, Ogedegbe G, Pbert L, Ruiz JM, Stevermer J, Wong JB. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022 08 23; 328(8):746-753.

View in: PubMed
Dillon GA, Stanhewicz AE, Serviente C, Flores VA, Stachenfeld N, Alexander LM. Seven days of statin treatment improves nitric-oxide mediated endothelial-dependent cutaneous microvascular function in women with endometriosis. Microvasc Res. 2022 11; 144:104421.

View in: PubMed
Santoni M, Molina-Cerrillo J, Myint ZW, Massari F, Buchler T, Buti S, Matrana MR, De Giorgi U, Rizzo M, Zabalza IO, Galli L, Zucali PA, Aurilio G, Incorvaia L, Bassanelli M, Mammone G, Salfi A, Isella L, Mollica V, Grande E, Porta C, Battelli N. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies. Target Oncol. 2022 09; 17(5):571-581.

View in: PubMed
Santoni M, Massari F, Matrana MR, Basso U, De Giorgi U, Aurilio G, Buti S, Incorvaia L, Rizzo M, Martignetti A, Maslov D, Tawagi K, Philon E, Blake Z, Porta C, Battelli N. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. Eur J Cancer. 2022 09; 172:191-198.

View in: PubMed
Santoni M, Monteiro FSM, Massari F, Abahssain H, Aurilio G, Molina-Cerrillo J, Myint ZW, Zabalza IO, Battelli N, Grande E. Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival. Crit Rev Oncol Hematol. 2022 Aug; 176:103731.

View in: PubMed

People

Explore

Similar Concepts

Top Journals